Novavax gains as South Korea clears use of COVID vaccine in adolescents

SK Bioscience Co

12/08/2022 16:00

** Shares of Novavax Inc  NVAX.O  jump ~7% to $43.06 in
morning trade 
    ** Vaccine maker receives approval in South Korea for use of
its COVID-19 vaccine, Nuvaxovid, in adolescents aged 12 through
17  urn:newsml:reuters.com:*:nPn90Lfkfa 
    ** NVAX and partner SK Bioscience Co  302440.KS  will
provide the vaccine in South Korea 
    ** NVAX recently expanded its vaccine deal with SK
Bioscience to manufacture and supply the vaccine in a pre-filled
syringe  urn:newsml:reuters.com:*:nL4N2Z0359 
    ** Co's protein-based COVID-19 vaccine has been granted
authorization in India, EU, Australia, Thailand and Japan, for
the 12- through 17-year-old population
    ** As of last close, NVAX down ~72% YTD 

 (Reporting by Bhanvi Satija in Bengaluru)
 ((Bhanvi.Satija@thomsonreuters.com; Outside U.S. +91
9873062788;))